446 patents currently held
21 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
176 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
177
Ending by 2030
Nov 2026
Next term end
215
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2029 · High confidence
Also notable
Ends May 2027 · High confidence
Also notable
Ends Aug 2027 · High confidence
Also notable
Ends Aug 2029 · Medium confidence
Also notable
Ends Apr 2034 · High confidence
Also notable
Ends no later than Feb 2033 · Medium confidence
Also notable
Ends Dec 2026 · Medium confidence
Also notable
Ends Dec 2026 · High confidence
Modulators of Atp-Binding Cassette Transporters
US 8,829,204
Cited by 141 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Modulators of Atp-Binding Cassette Transporters
US 7,659,268
Cited by 166 later US patents, top 5% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Modulators of Atp-Binding Cassette Transporters
US 8,623,905
Cited by 123 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Pharmaceutical Composition and Administrations Thereof
US 10,646,481
Cited by 67 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2029.
Compounds Useful as Inhibitors of Atr Kinase
US 9,340,546
Cited by 106 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Pharmaceutical Composition and Administrations Thereof
US 10,272,046
Cited by 56 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2033. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Solid Forms of N-[2,4-BIS(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
US 10,537,565
Cited by 37 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2026.
Modulators of Atp-Binding Cassette Transporters
US 7,973,169
Cited by 144 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2026.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Nov 26 to 28, 2026 · next Nov 26
- 8 fees due Dec 2 to 30, 2026 · next Dec 2
- 2 fees due Jan 14 to 25, 2027 · next Jan 14
- 6 fees due Feb 4 to 27, 2027 · next Feb 4
- 4 fees due Mar 10 to 22, 2027 · next Mar 10
- 6 fees due Apr 3 to 30, 2027 · next Apr 3
- 10 fees due May 7 to 28, 2027 · next May 7
- 2 fees due Jun 5 to 10, 2027 · next Jun 5
- 5 fees due Jul 9 to 30, 2027 · next Jul 9
- 3 fees due Aug 2 to 25, 2027 · next Aug 2
- 5 fees due Sep 5 to 29, 2027 · next Sep 5
- 6 fees due Oct 2 to 26, 2027 · next Oct 2
- 7 fees due Nov 10 to 19, 2027 · next Nov 10
Recent changes
- 2 of the patents on this record were granted since Aug 22, 2026
- 19 terms have ended since Aug 22, 2026
- Nov 16 US 7,972,813 Tetrodotoxin-Resistant Sodium Channel Alpha Subunit · term ended
- Nov 8 US 9,216,969 Modulators of Atp-Binding Cassette Transporters · term ended
- Nov 8 US 8,993,600 Modulators of Atp-Binding Cassette Transporters · term ended
- Nov 8 US 8,741,933 Modulators of Atp-Binding Cassette Transporters · term ended
- Nov 8 US 8,461,156 Modulators of ATP-Binding Cassette Transporters · term ended
- Nov 8 US 8,324,207 Modulators of Atp-Binding Cassette Transporters · term ended
- Nov 8 US 8,318,733 Modulators of Atp-Binding Cassette Transporters · term ended
- Nov 8 US 7,973,038 Modulators of Atp-Binding Cassette Transporters · term ended
- Nov 8 US 7,956,052 Modulators of Atp-Binding Cassette Transporters · term ended
- Nov 3 US 8,129,399 Aminopyrimidines Useful as Kinase Inhibitors · term ended
- Nov 3 US 7,820,685 Aminopyrimidines Useful as Kinase Inhibitors · term ended
- Nov 3 US 7,528,142 Aminopyrimidines Useful as Kinase Inhibitors · term ended
- Oct 21 US 8,865,771 Amides Useful as Inhibitors of Voltage-Gated Sodium Channels · lapsed on the fee record
- Oct 21 US 7,880,008 Heterocycles Useful as Modulators of Ion Channels · term ended
- Oct 11 US 11,464,774 Method for Treating Cancer Using a Combination of DNA Damaging Agents and Atr Inhibitors · lapsed on the fee record
What they patent
The largest of its 215 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,767,672 | Aminopyrimidines Useful as Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 7,973,169 | Modulators of Atp-Binding Cassette Transporters In force · High confidence | In force | High confidence | |
| US 8,586,589 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels In force · High confidence | In force | High confidence | |
| US 7,691,902 | Modulators of Atp-Binding Cassette Transporters In force · High confidence | In force | High confidence | |
| US 8,410,274 | Solid Forms of N-[2,4-BIS(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide In force · Low confidence | In force | Low confidence | |
| US 8,754,224 | Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide In force · Low confidence | In force | Low confidence | |
| US 8,846,753 | Modulators of Atp-Binding Cassette Transporters In force · High confidence | In force | High confidence | |
| US 9,139,530 | Solid Forms of N-[2,4-BIS(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide In force · Medium confidence | In force | Medium confidence | |
| US 9,670,163 | Solid Forms of N-[2,4-BIS(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide In force · Low confidence | In force | Low confidence | |
| US 10,537,565 | Solid Forms of N-[2,4-BIS(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 446: 21 patents in force now held by others · 442 patents ended · 138 applications pending · 385 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.